Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 11/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 11/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980928 | 0.90 | TOP2A (0.62) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL3984146 | 0.88 | TOP2A (0.52) | TOP2ATOP2BKDM1AJAK2MEN1 | |
| SCHEMBL5428900 | 0.85 | TOP2A (0.52) | TOP2ATOP2BKDM1APARP1POLB | |
| SCHEMBL3981078 | 0.85 | TOP2A (0.52) | TOP2ATOP2BKDM1APARP1POLB | |
| SCHEMBL3987573 | 0.85 | TOP2A (0.56) | TOP2ATOP2BKDM1AMEN1NPC1 | |
| SCHEMBL3981536 | 0.82 | TOP2A (0.61) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3986033 | 0.81 | TOP2A (0.60) | TOP2ATOP2BMEN1NPC1GAA | |
| SCHEMBL3986028 | 0.81 | TOP2A (0.61) | TOP2ATOP2BKDM1APOLBRAD52 | |
| SCHEMBL5405660 | 0.80 | TOP2A (0.41) | TOP2ATOP2BKDM1APARP1POLB | |
| SCHEMBL3980933 | 0.80 | TOP2A (0.58) | TOP2ATOP2BSUV39H2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380574-B1 | 9-aminoacridine derivates and process for the preparation thereof | SAMJIN PHARM CO LTD (KR) | 2009-05-20 | — | — | EP | disclosed |
| EP-1380574-A1 | 9-aminoacridine derivates and process for the preparation thereof | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-01-14 | — | — | EP | disclosed |
| US-6620936-B2 | Antitumor agents, topoisomerase inhibitors, notoxic | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | TOP2A 1105/4885TOP2B 841/4885KDM1A 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.